JP2010189403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010189403A5 JP2010189403A5 JP2010075835A JP2010075835A JP2010189403A5 JP 2010189403 A5 JP2010189403 A5 JP 2010189403A5 JP 2010075835 A JP2010075835 A JP 2010075835A JP 2010075835 A JP2010075835 A JP 2010075835A JP 2010189403 A5 JP2010189403 A5 JP 2010189403A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- opioid
- acyl
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 vegitramide Chemical compound 0.000 claims 87
- 150000003839 salts Chemical class 0.000 claims 57
- 125000002252 acyl group Chemical group 0.000 claims 39
- 239000003401 opiate antagonist Substances 0.000 claims 32
- 230000037317 transdermal delivery Effects 0.000 claims 28
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 12
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 12
- LGFMXOTUSSVQJV-NEYUFSEYSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(4r,4ar,7s,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol;1-[(3,4-dimethoxyphenyl)methyl]-6 Chemical compound Cl.Cl.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 LGFMXOTUSSVQJV-NEYUFSEYSA-N 0.000 claims 10
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 10
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 10
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 10
- 229960001410 hydromorphone Drugs 0.000 claims 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 8
- 229930195729 fatty acid Natural products 0.000 claims 8
- 239000000194 fatty acid Substances 0.000 claims 8
- 150000004665 fatty acids Chemical class 0.000 claims 8
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 7
- 229960001736 buprenorphine Drugs 0.000 claims 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 7
- 229960002428 fentanyl Drugs 0.000 claims 7
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 7
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 7
- 229960000240 hydrocodone Drugs 0.000 claims 7
- 229960002085 oxycodone Drugs 0.000 claims 7
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 7
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 6
- 229960005297 nalmefene Drugs 0.000 claims 6
- 229960004127 naloxone Drugs 0.000 claims 6
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 6
- 229960003086 naltrexone Drugs 0.000 claims 6
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 6
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 5
- BQJCRHHNABKAKU-NOSXKOESSA-N (4r,4ar,7r,7ar,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O([C@H]1[C@@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-NOSXKOESSA-N 0.000 claims 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 5
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 5
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 5
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 5
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 5
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 5
- 229930194542 Keto Natural products 0.000 claims 5
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 5
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 5
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 5
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 5
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 5
- 239000008896 Opium Substances 0.000 claims 5
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 5
- 229960001391 alfentanil Drugs 0.000 claims 5
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 5
- 229960002512 anileridine Drugs 0.000 claims 5
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 5
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 5
- 229960001113 butorphanol Drugs 0.000 claims 5
- 229960004126 codeine Drugs 0.000 claims 5
- XBRXTUGRUXGBPX-DLBZAZTESA-N cyclazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N([C@@H]1CCCC[C@@H]11)CCN1C(=O)C1=CC=CO1 XBRXTUGRUXGBPX-DLBZAZTESA-N 0.000 claims 5
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 5
- 229950003851 desomorphine Drugs 0.000 claims 5
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 5
- 229960003701 dextromoramide Drugs 0.000 claims 5
- 229960004193 dextropropoxyphene Drugs 0.000 claims 5
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 5
- 229960003461 dezocine Drugs 0.000 claims 5
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 5
- 229960002069 diamorphine Drugs 0.000 claims 5
- 229960000920 dihydrocodeine Drugs 0.000 claims 5
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 5
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 5
- 229950011187 dimenoxadol Drugs 0.000 claims 5
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 5
- CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 claims 5
- 229950005563 dimethylthiambutene Drugs 0.000 claims 5
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 5
- 229960002500 dipipanone Drugs 0.000 claims 5
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 5
- 229950010920 eptazocine Drugs 0.000 claims 5
- MORSAEFGQPDBKM-UHFFFAOYSA-N ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 claims 5
- 229950006111 ethylmethylthiambutene Drugs 0.000 claims 5
- 229960004578 ethylmorphine Drugs 0.000 claims 5
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 5
- 229950004155 etorphine Drugs 0.000 claims 5
- 230000002743 euphoric effect Effects 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 5
- 229950009272 isomethadone Drugs 0.000 claims 5
- 229960003406 levorphanol Drugs 0.000 claims 5
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 5
- 229950010274 lofentanil Drugs 0.000 claims 5
- 229960000365 meptazinol Drugs 0.000 claims 5
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 5
- YEOTYALSMRNXLJ-UHFFFAOYSA-N metazosin Chemical compound C1CN(C(=O)C(C)OC)CCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 YEOTYALSMRNXLJ-UHFFFAOYSA-N 0.000 claims 5
- 229960001797 methadone Drugs 0.000 claims 5
- 229960005181 morphine Drugs 0.000 claims 5
- 229960000805 nalbuphine Drugs 0.000 claims 5
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 5
- 229960000938 nalorphine Drugs 0.000 claims 5
- 229960004300 nicomorphine Drugs 0.000 claims 5
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 5
- 229950011519 norlevorphanol Drugs 0.000 claims 5
- 229950006134 normorphine Drugs 0.000 claims 5
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 5
- 229950007418 norpipanone Drugs 0.000 claims 5
- 229960001027 opium Drugs 0.000 claims 5
- 229960005118 oxymorphone Drugs 0.000 claims 5
- 229960003294 papaveretum Drugs 0.000 claims 5
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 5
- 229960005301 pentazocine Drugs 0.000 claims 5
- 229960000482 pethidine Drugs 0.000 claims 5
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 5
- 229950011496 phenomorphan Drugs 0.000 claims 5
- 229960004315 phenoperidine Drugs 0.000 claims 5
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 5
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 5
- 229950004345 properidine Drugs 0.000 claims 5
- 229960004739 sufentanil Drugs 0.000 claims 5
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 5
- 229960004380 tramadol Drugs 0.000 claims 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 5
- 239000000853 adhesive Substances 0.000 claims 4
- 230000001070 adhesive effect Effects 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 2
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 150000001370 alpha-amino acid derivatives Chemical group 0.000 claims 2
- 235000008206 alpha-amino acids Nutrition 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003887 narcotic antagonist Substances 0.000 claims 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35714102P | 2002-02-19 | 2002-02-19 | |
| US35713902P | 2002-02-19 | 2002-02-19 | |
| US60/357,141 | 2002-02-19 | ||
| US60/357,139 | 2002-02-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569151A Division JP4874523B2 (ja) | 2002-02-19 | 2003-02-19 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160887A Division JP2013237692A (ja) | 2002-02-19 | 2013-08-02 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010189403A JP2010189403A (ja) | 2010-09-02 |
| JP2010189403A5 true JP2010189403A5 (enExample) | 2011-03-03 |
| JP5453151B2 JP5453151B2 (ja) | 2014-03-26 |
Family
ID=27760456
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569151A Expired - Fee Related JP4874523B2 (ja) | 2002-02-19 | 2003-02-19 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
| JP2010075835A Expired - Fee Related JP5453151B2 (ja) | 2002-02-19 | 2010-03-29 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
| JP2013160887A Pending JP2013237692A (ja) | 2002-02-19 | 2013-08-02 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003569151A Expired - Fee Related JP4874523B2 (ja) | 2002-02-19 | 2003-02-19 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013160887A Pending JP2013237692A (ja) | 2002-02-19 | 2013-08-02 | 不正使用防止機能付きの経皮的オピオイド送給装置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040033253A1 (enExample) |
| EP (1) | EP1476141B1 (enExample) |
| JP (3) | JP4874523B2 (enExample) |
| AT (1) | ATE392892T1 (enExample) |
| AU (1) | AU2003216321A1 (enExample) |
| CY (1) | CY1108201T1 (enExample) |
| DE (1) | DE60320530T2 (enExample) |
| DK (1) | DK1476141T3 (enExample) |
| ES (1) | ES2305480T3 (enExample) |
| PT (1) | PT1476141E (enExample) |
| SI (1) | SI1476141T1 (enExample) |
| WO (1) | WO2003070191A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| ES2323127T3 (es) * | 2002-08-20 | 2009-07-07 | Euro-Celtique S.A. | Forma posologica transdermica que comprende un agente activo y una forma de sal y una forma de base libre de un antagonista. |
| US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| BRPI0409945A (pt) * | 2003-04-30 | 2006-04-25 | Purdue Pharma Lp | forma de dosagem resistente à alteração |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US7867511B2 (en) * | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US9056061B2 (en) | 2005-09-23 | 2015-06-16 | Alza Corporation | Transdermal nicotine salt delivery system |
| EP2308480B1 (en) | 2005-09-23 | 2014-08-13 | ALZA Corporation | High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications |
| US9522188B2 (en) | 2005-12-13 | 2016-12-20 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| ES2577390T3 (es) | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Dispositivos de administración transmucosa con mayor captación |
| DE202006018609U1 (de) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung |
| ES2549115T3 (es) * | 2006-09-22 | 2015-10-23 | Zynerba Pharmaceuticals, Inc. | Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos |
| TWI454288B (zh) | 2008-01-25 | 2014-10-01 | Gruenenthal Chemie | 藥物劑型 |
| US9700552B2 (en) | 2008-02-28 | 2017-07-11 | Syntropharma Limited | Pharmaceutical compositions for treatment of addiction |
| CA2718943A1 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| EP2291380B1 (en) * | 2008-04-24 | 2011-09-07 | Janssen Pharmaceutica N.V. | Nalmefene prodrugs |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| US10363251B2 (en) | 2009-07-16 | 2019-07-30 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| BR112012001466A2 (pt) | 2009-07-22 | 2020-08-11 | Grünenthal GmbH | forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem |
| ES2534908T3 (es) | 2009-07-22 | 2015-04-30 | Grünenthal GmbH | Forma de dosificación de liberación controlada extruida por fusión en caliente |
| WO2012008984A1 (en) | 2010-07-16 | 2012-01-19 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| WO2012028318A1 (en) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polymer |
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
| JP6063462B2 (ja) | 2011-07-29 | 2017-01-18 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 即時薬剤放出を提供するタンパーレジスタント錠剤 |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| LT2838512T (lt) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| WO2014152009A1 (en) * | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| KR20160034352A (ko) | 2013-07-23 | 2016-03-29 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
| HK1224189A1 (zh) | 2013-11-26 | 2017-08-18 | Grünenthal GmbH | 通过低温研磨制备粉状药物组合物 |
| WO2015082932A1 (en) * | 2013-12-05 | 2015-06-11 | The University Of Bath | Novel opioid compounds and their uses |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| CA2969221C (en) * | 2014-12-02 | 2021-01-12 | Travis Mickle | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof |
| US10010543B1 (en) | 2014-12-23 | 2018-07-03 | Barr Laboratories, Inc. | Transdermal dosage form |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| WO2016170097A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| GB201520390D0 (en) * | 2015-11-19 | 2016-01-06 | Euro Celtique Sa | Composition |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| JP7369687B2 (ja) * | 2017-07-20 | 2023-10-26 | スーチョウ ランシンダタイ ファーマシューティクス エルティーディー シーオー． | 乱用防止長期作用型徐放性オピオイドプロドラッグ |
| EP3703694A4 (en) | 2017-11-03 | 2021-08-18 | Nirsum Laboratories, Inc. | MEDICINES ANTAGONISTS OF OPIOID RECEPTORS |
| CA3091826A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
| US10807995B2 (en) | 2018-07-13 | 2020-10-20 | Alkermes Pharma Ireland Limited | Thienothiophene compounds for long-acting injectable compositions and related methods |
| US11186585B2 (en) | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| KR20210078515A (ko) * | 2018-10-18 | 2021-06-28 | 아비어, 인크. | 만성 신장 질환-연관 소양증의 치료 방법 및 장치 |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| WO2020223894A1 (en) | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
| CA3149152A1 (en) | 2019-08-11 | 2021-02-18 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| WO2021219576A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Multiparticulate dosage form containing eva copolymer and additional excipient |
| WO2021219577A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Dosage form comprising hot-melt extruded pellets containing eva copolymer and gliding agent |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3527864A (en) * | 1966-11-18 | 1970-09-08 | Procter & Gamble | Compositions for topical application to animal tissue and method of enhancing penetration thereof |
| US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
| US3903256A (en) * | 1972-02-07 | 1975-09-02 | Procter & Gamble | Compositions for topical application of animal tissue and method of enhancing penetration thereof |
| US3896238A (en) * | 1972-04-05 | 1975-07-22 | Procter & Gamble | Dermatological compositions |
| DE2323192A1 (de) * | 1972-05-10 | 1973-12-13 | Endo Lab | Injizierbare, langwirkende antagonistpraeparate gegen narkotika und rauschgifte |
| US3952099A (en) * | 1973-03-13 | 1976-04-20 | The Procter & Gamble Company | Dermatological compositions |
| US4006218A (en) * | 1974-07-08 | 1977-02-01 | Johnson & Johnson | Potentiated medicaments |
| US4046886A (en) * | 1975-01-17 | 1977-09-06 | The Procter & Gamble Company | Dermatological compositions |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4130643A (en) * | 1976-01-12 | 1978-12-19 | The Procter & Gamble Company | Dermatological compositions |
| US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
| US4060084A (en) * | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4335115A (en) * | 1976-11-01 | 1982-06-15 | The Procter & Gamble Company | Anti-acne composition |
| US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
| US4299826A (en) * | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
| US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4343798A (en) * | 1981-06-23 | 1982-08-10 | The Procter & Gamble Company | Topical antimicrobial anti-inflammatory compositions |
| US4560553A (en) * | 1981-07-07 | 1985-12-24 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| ZA855058B (en) * | 1984-07-05 | 1987-03-25 | Du Pont | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans,intermediates thereto,and processes |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| JPS61103840A (ja) * | 1984-10-26 | 1986-05-22 | Nitto Electric Ind Co Ltd | 外皮投与用組成物 |
| US4775759A (en) * | 1984-11-27 | 1988-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT) |
| US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| US5066648A (en) * | 1985-11-29 | 1991-11-19 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
| US4722928A (en) * | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
| US4990617A (en) * | 1985-12-02 | 1991-02-05 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans and derivatives |
| US4973968A (en) * | 1986-03-07 | 1990-11-27 | Plessey Overseas Limited | Radar system for determining first time around targets from multiple time around targets |
| US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
| US4769372A (en) * | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US4940586A (en) * | 1987-02-26 | 1990-07-10 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US4900555A (en) * | 1987-02-26 | 1990-02-13 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
| US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
| EP0299549A3 (en) * | 1987-07-09 | 1989-02-08 | Duphar International Research B.V | Tertiary 2,5-dialkyl-3-phenyl-piperidine derivatives having opiate-antagonistic activity |
| US4879275A (en) * | 1987-09-30 | 1989-11-07 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agent |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| US5405486A (en) * | 1988-03-04 | 1995-04-11 | Noven Pharmaceuticals, Inc. | Apparatus for forming a transdermal drug device |
| US5164406A (en) * | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
| US5641504A (en) * | 1988-06-09 | 1997-06-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolinoleate |
| US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
| US4960771A (en) * | 1988-07-12 | 1990-10-02 | Rajadhyaksha Vithal J | Oxazolidinone penetration enhancing compounds |
| US5236714A (en) * | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US5194581A (en) * | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
| US5256765A (en) * | 1989-03-09 | 1993-10-26 | The Johns Hopkins University School Of Medicine | Biodegradable poly(phosphate esters) |
| US5059426A (en) * | 1989-03-22 | 1991-10-22 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
| US5053227A (en) * | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
| US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
| US5096715A (en) * | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| US5326566A (en) * | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| US5227169A (en) * | 1991-05-17 | 1993-07-13 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| AU660336B2 (en) * | 1991-10-18 | 1995-06-22 | Alza Corporation | Device for the transdermal administration of melatonin |
| US5238933A (en) * | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
| US5229130A (en) * | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| AU670777B2 (en) * | 1992-04-16 | 1996-08-01 | Ortho Pharmaceutical Corporation | Aqueous gel vehicles for retinoids |
| US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| US5352680A (en) * | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
| US5308625A (en) * | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
| US6162456A (en) * | 1992-09-24 | 2000-12-19 | Ortho-Mcneil Pharmaceutical, Inc. | Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers |
| AU7396294A (en) * | 1993-06-25 | 1995-01-24 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
| NZ274711A (en) * | 1993-09-29 | 1996-11-26 | Alza Corp | Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s) |
| JP3021661B2 (ja) * | 1994-03-07 | 2000-03-15 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
| US5750534A (en) * | 1994-03-16 | 1998-05-12 | National Science Council | Nalbuphine esters having long acting analgesic action and method of use |
| US5420106A (en) * | 1994-03-22 | 1995-05-30 | Bristol-Myers Squibb Company | Method and composition having enhanced alpha-hydroxy acid skin permeation and retention |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5665378A (en) * | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
| US5882676A (en) * | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
| US5693335A (en) * | 1995-06-07 | 1997-12-02 | Cygnus, Inc. | Skin permeation enhancer composition for use with sex steroids |
| US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| US5902603A (en) * | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
| PT914097E (pt) * | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
| US5914718A (en) * | 1996-06-26 | 1999-06-22 | Xerox Corporation | Method and apparatus for organizing a work space for a computer controlled display system using borders and regions |
| US5837289A (en) * | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
| ES2191834T3 (es) * | 1996-10-24 | 2003-09-16 | Alza Corp | Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos. |
| US5912009A (en) * | 1996-10-30 | 1999-06-15 | Theratech, Inc. | Fatty acid esters of glycolic acid and its salts |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
| CN1204890C (zh) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| AU754965B2 (en) * | 1997-12-31 | 2002-11-28 | University Of Kansas, The | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| SI2283842T1 (sl) * | 2000-02-08 | 2015-07-31 | Euro-Celtique S.A. | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| AU4743601A (en) * | 2000-03-15 | 2001-09-24 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
-
2003
- 2003-02-14 US US10/366,394 patent/US20040033253A1/en not_active Abandoned
- 2003-02-19 EP EP03742830A patent/EP1476141B1/en not_active Expired - Lifetime
- 2003-02-19 SI SI200331243T patent/SI1476141T1/sl unknown
- 2003-02-19 DE DE60320530T patent/DE60320530T2/de not_active Expired - Lifetime
- 2003-02-19 AT AT03742830T patent/ATE392892T1/de active
- 2003-02-19 DK DK03742830T patent/DK1476141T3/da active
- 2003-02-19 ES ES03742830T patent/ES2305480T3/es not_active Expired - Lifetime
- 2003-02-19 JP JP2003569151A patent/JP4874523B2/ja not_active Expired - Fee Related
- 2003-02-19 WO PCT/US2003/004999 patent/WO2003070191A2/en not_active Ceased
- 2003-02-19 AU AU2003216321A patent/AU2003216321A1/en not_active Abandoned
- 2003-02-19 PT PT03742830T patent/PT1476141E/pt unknown
-
2008
- 2008-07-17 CY CY20081100746T patent/CY1108201T1/el unknown
-
2010
- 2010-03-29 JP JP2010075835A patent/JP5453151B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-02 JP JP2013160887A patent/JP2013237692A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011515495A5 (enExample) | ||
| US5149538A (en) | Misuse-resistive transdermal opioid dosage form | |
| JP2006524261A5 (enExample) | ||
| JP2024015430A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| US20040033253A1 (en) | Acyl opioid antagonists | |
| JP2014088422A5 (enExample) | ||
| JP2012519675A5 (enExample) | ||
| CO6150130A2 (es) | Liberacion controlada de formulaciones y metodos asociados | |
| CA2654700A1 (en) | Transdermal patch | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| TWI522101B (zh) | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 | |
| JP2009541320A5 (enExample) | ||
| RU2009101082A (ru) | Фармацевтические композиции | |
| RU2007139827A (ru) | Фармацевтические композиции для лечения боли | |
| EP1981502A2 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| WO2017125455A1 (en) | Transdermal patch | |
| RU2012124063A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
| JP2013510842A5 (enExample) | ||
| US9849124B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
| US10406154B2 (en) | Transdermal dosage form | |
| WO2020009685A1 (en) | Transdermal dosage form | |
| JP2018534319A5 (enExample) | ||
| US20180344726A1 (en) | Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain |